Abstract-Metastasis through the bloodstream contributes to poor prognosis in many types of cancer. Mounting evidence implicates selectin-based adhesive interactions between cancer cells and the blood vessel wall as facilitating this process, in a manner similar to leukocyte trafficking during inflammation. Here, we describe a unique approach to target and kill colon and prostate cancer cells in the blood that causes circulating leukocytes to present the cancer-specific apoptosis ligand TRAIL on their surface along with E-selectin adhesion receptor. This approach, demonstrated in vitro with human blood and also in mice, mimics the cytotoxic activity of natural killer cells and increases the surface area available for delivery of the receptormediated signal. The resulting "unnatural killer cells" hold promise as an effective means to neutralize circulating tumor cells that enter blood with the potential to form new metastases.
INTRODUCTION
Hematogenous metastasis contributes to a poor patient prognosis in many types of cancer, with over 90% of cancerrelated death attributed to metastasis [1] . For metastasis to occur, cancer cells detach from the primary tumor, invade through the basement membrane, and intravasate into the peripheral circulation as circulating tumor cells (CTCs). It is believed that adhesive interactions between selectins on the blood vessel wall and selectin ligands on the CTC surface facilitate metastatic progression, in a manner similar to the leukocyte adhesion cascade essential in the inflammatory response. Here, we describe a novel approach to functionalize leukocytes with tumor necrosis factor-related apoptosisinducing ligand (TRAIL) on their surface, along with Eselectin (ES), to capture and induce cancer cell apoptosis both in vitro in human blood and in vivo in mouse circulation.
II. MATERIALS AND METHODS
Liposomes and COLO 205 or PC-3 cancer cells suspended in buffer or spiked in peripheral human blood samples were subjected to shear flow for 2 h in a cone-and-plate device [2] . Cancer cells and mononuclear cells were collected, washed and separated using a Ficoll density gradient [3] . Cells were cultured for 12-18 h and then analyzed for viability using flow cytometry (FC). In a separate experiment, liposomes were sheared in blood for 30 min, and liposome-coated blood cells were separated from unbound liposomes via centrifugation. Cancer cells were then sheared in a cone-and-plate viscometer for 2 h with pretreated blood cells [4] . To examine liposome adhesion, leukocytes were separated from blood using 1-Step Polymorphs and were identified using flow cytometry by labeling for CD3, CD14, CD16, CD19 and CD56. Fluorescent liposomes were visualized on the leukocyte membrane via confocal microscopy [5] .
For in vivo studies, mice were injected with saline, sTRAIL, ES liposomes, or ES/TRAIL liposomes retroorbitally and 30 min later were injected with Hoechst-labeled COLO 205 cells through the tail vein. In some mice, a lethal 978-1-4799-3728-8/14/$31.00 ©2014 IEEE dose of pentobarbital was given after 2 h and blood removed via cardiac puncture and analyzed using FC to determine counts of circulating COLO 205 cells. In other animals, an Annexin-V apoptosis probe was injected and allowed to circulate for an additional 2 h before animals were euthanized and the lungs removed for two-photon excited fluorescence (2PEF) imaging, to determine counts of COLO 205 cells lodged in the lung, and the fraction that was apoptotic.
III. RESULTS AND DISCUSSION
To target and kill cancer cells under blood flow conditions, we developed nanoscale liposomes conjugated with a mixture ES and TRAIL. TRAIL binds to death receptors 4 and 5 on the surface of cancer cells to induce apoptosis, but has no effect on most types of nontransformed cells. ES/TRAIL liposomes were found to target and induce apoptosis in cancer cell lines under static culture or when sheared with a coneand-plate viscometer in a dilute suspension, while having minimal effect on leukocytes in blood. Experiments comparing ES/TRAIL liposomes to TRAIL-only liposomes suggest that the presence of the ES adhesion receptor enhances the effect of TRAIL by promoting tighter contacts with the cancer cell membrane.
To examine whether ES/TRAIL liposomes would effectively target cancer cells in the presence of blood cells and serum under flow conditions, we fluorescently labeled the colorectal cancer line COLO 205 and spiked them into human peripheral blood. Surprisingly, the ES/TRAIL liposomes were more effective at killing cancer cells in the presence of blood, compared to shearing COLO 205 cells alone in buffer, in a blood cell dose-dependent manner. Similar results were seen with the human prostate cancer cell line PC-3.
ES functionalized liposomes readily bind to leukocytes via PSGL-1 and L-selectin receptors on the leukocyte surface [6] . Thus, upon addition of the ES/TRAIL liposomes to cancer cell-spiked blood, liposomes attach to the surface of leukocytes, and are available for inducing apoptosis in cancer cells that they come into contact with (Fig. 1A) . This mechanism, in which leukocytes act as a pervading carrier surface for functional TRAIL, is supported by further experiments in which blood was pretreated with ES/TRAIL liposomes and then separated from unbound liposomes by centrifugation. Over 95% of cancer cells were killed after exposure to ES/TRAIL-functionalized leukocytes in blood under flow, compared to controls (Fig. 1B) . Flow cytometry analysis revealed that all the major peripheral leukocyte subpopulations bind to ES/TRAIL liposomes to varying degrees, including lymphocytes, which suggests that cytotoxic patrolling of the lymphatic system may occur in vivo.
ES/TRAIL liposomes were also tested for their ability to kill cancer cells flowing in the peripheral circulation of mice. Two million fluorescently labeled COLO 205 cells were injected into the tail vein of immunocompetent C57BL/6J mice, 30 min after injection of either ES/TRAIL liposomes, ES liposomes, or soluble TRAIL. After 2 h, animals were sacrificed, cancer cells were recovered from the circulation and placed back into culture. Using flow cytometry, we measured ~130,000 cancer cells/mL blood for mice injected with control ES liposomes, compared to <2,000 cancer cells/mL blood surviving from ES/TRAIL treated mice. Mice injected with buffer or soluble TRAIL had intermediate numbers of cells, likely indicating that ES functionalized liposomes help to retain cancer cells in the circulation by blocking selectin-mediated interaction with the endothelium. Cancer cells isolated from mice treated with control treatments exhibited a normal, round morphology, whereas cancer cells from ES/TRAIL liposome treated mice showed notable membrane blebbing (Fig. 1C) . Fluorescent ES/TRAIL liposomes were clearly visible on the surface of leukocytes recovered from mouse blood.
Because cancer cells injected into the tail vein can lodge in the lung, we examined cancer cell number and viability in the lungs of mice using two-photon excited fluorescence microscopy. We found a decreased density of cancer cells as well as a dramatic increase in apoptosis of the cancer cells in the ES/TRAIL liposome treated mice as compared with other groups. Soluble TRAIL protein injected into mice following the same protocol displayed minimal cytotoxic activity comparable to control, as expected due to its short circulation half-life. Mice injected with ES/TRAIL liposomes survived for over two weeks with no loss in body weight.
IV. CONCLUSIONS
We have shown that leukocytes functionalized with ES/TRAIL can capture and induce cancer cell apoptosis in vitro in human blood and in vivo in mouse experiments. ES/TRAIL-functionalized leukocytes can form the basis of a novel method to target CTCs in the bloodstream as a means to prevent cancer metastasis. Clinically, this therapeutic strategy can serve as preventive measure upon diagnosis of metastatic hematogenous cancers.
